Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A7394

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Cardiotoxicity - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
4.4 Market Overview (2019-2024) and Forecast (2025-2035)
4.5 Competitive Intelligence

5 Cardiotoxicity - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Cardiotoxicity - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Diagnosed Cases (2019-2035)
7.2.6 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Diagnosed Cases (2019-2035)
7.3.6 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Diagnosed Cases (2019-2035)
7.4.6 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.5.4 Epidemiology by Gender (2019-2035)
7.5.5 Diagnosed Cases (2019-2035)
7.5.6 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Diagnosed Cases (2019-2035)
7.6.6 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Diagnosed Cases (2019-2035)
7.7.6 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Diagnosed Cases (2019-2035)
7.8.6 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Diagnosed Cases (2019-2035)
7.9.6 Patient Pool/Treated Cases (2019-2035)

8 Cardiotoxicity - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Cardiotoxicity - Unmet Needs

10 Cardiotoxicity - Key Endpoints of Treatment

11 Cardiotoxicity - Marketed Products
11.1 List of Cardiotoxicity Marketed Drugs Across the Top 7 Markets
10.1.1 Dexrazoxane - Novartis

10.1.1.1 Drug Overview
10.1.1.2 Mechanism of Action
10.1.1.3 Regulatory Status
10.1.1.4 Clinical Trial Results
10.1.1.5 Sales Across Major Markets
10.2.1 Spironolactone - Pfizer
10.2.1.1 Drug Overview
10.2.1.2 Mechanism of Action
10.2.1.3 Regulatory Status
10.2.1.4 Clinical Trial Results
10.2.1.5 Sales Across Major Markets
10.3.1 Enalapril - Silvergate Pharmaceuticals
10.3.1.1 Drug Overview
10.3.1.2 Mechanism of Action
10.3.1.3 Regulatory Status
10.3.1.4 Clinical Trial Results
10.3.1.5 Sales Across Major Markets
10.4.1 Nebivolol - Janssen/ Forest Laboratories
10.4.1.1 Drug Overview
10.4.1.2 Mechanism of Action
10.4.1.3 Regulatory Status
10.4.1.4 Clinical Trial Results
10.4.1.5 Sales Across Major Markets
10.5.1 Perindopril - Symplmed
10.5.1.1 Drug Overview
10.5.1.2 Mechanism of Action
10.5.1.3 Regulatory Status
10.5.1.4 Clinical Trial Results
10.5.1.5 Sales Across Major Markets
10.6.1 Candesartan - AstraZeneca/Takeda
10.6.1.1 Drug Overview
10.6.1.2 Mechanism of Action
10.6.1.3 Regulatory Status
10.6.1.4 Clinical Trial Results
10.6.1.5 Sales Across Major Markets
10.7.1 Telmisartan - Boehringer Ingelheim
10.7.1.1 Drug Overview
10.7.1.2 Mechanism of Action
10.7.1.3 Regulatory Status
10.7.1.4 Clinical Trial Results
10.7.1.5 Sales Across Major Markets
10.8.1 Atorvastatin - Pfizer
10.8.1.1 Drug Overview
10.8.1.2 Mechanism of Action
10.8.1.3 Regulatory Status
10.8.1.4 Clinical Trial Results
10.8.1.5 Sales Across Major Markets
10.9.1 Bisoprolol - Aurobindo Pharma
10.9.1.1 Drug Overview
10.9.1.2 Mechanism of Action
10.9.1.3 Regulatory Status
10.9.1.4 Clinical Trial Results
10.9.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Cardiotoxicity - Pipeline Drugs
12.1 List of Cardiotoxicity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. Cardiotoxicity - Attribute Analysis of Key Marketed and Pipeline Drugs
 
14. Cardiotoxicity – Clinical Trial Landscape

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Cardiotoxicity - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets

15.2.1    Cardiotoxicity - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2    Cardiotoxicity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2025-2035)
15.3 Market Scenario - United States
15.3.1    Cardiotoxicity - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2    Cardiotoxicity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3    Cardiotoxicity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1    Cardiotoxicity - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2    Cardiotoxicity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3    Cardiotoxicity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1    Cardiotoxicity - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2    Cardiotoxicity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3    Cardiotoxicity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1    Cardiotoxicity - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2    Cardiotoxicity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3    Cardiotoxicity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1    Cardiotoxicity - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2    Cardiotoxicity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3    Cardiotoxicity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1    Cardiotoxicity - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2    Cardiotoxicity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3    Cardiotoxicity - Access and Reimbursement Overview
15.9   Market Scenario - Japan
15.9.1    Cardiotoxicity  - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2    Cardiotoxicity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3    Cardiotoxicity - Access and Reimbursement Overview

16 Cardiotoxicity - Recent Events and Inputs From Key Opinion Leaders

17 Cardiotoxicity Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats  
   
18 Cardiotoxicity Market – Strategic Recommendations

19 Appendix

Cardiotoxicity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials